These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
439 related items for PubMed ID: 14524737
41. Lercanidipine in hypertension. Borghi C. Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103 [Abstract] [Full Text] [Related]
42. Fixed-dose combination lercanidipine/enalapril. Hair PI, Scott LJ, Perry CM. Drugs; 2007; 67(1):95-106; discussion 107-8. PubMed ID: 17209666 [Abstract] [Full Text] [Related]
43. An assessment of lacidipine and atenolol in mild to moderate hypertension. Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. Br J Clin Pharmacol; 1994 Jan; 37(1):45-51. PubMed ID: 8148217 [Abstract] [Full Text] [Related]
45. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Muijsers RB, Curran MP, Perry CM. Drugs; 2002 Jan; 62(17):2539-67. PubMed ID: 12421112 [Abstract] [Full Text] [Related]
46. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Luque Otero M, Martell Claros N, Study Investigators Group. Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479 [Abstract] [Full Text] [Related]
47. Radial artery compliance in essential hypertension: effects of antihypertensive therapy with lacidipine. Trazzi S, Santucciu C, Mancia G. J Hypertens Suppl; 1993 Dec; 11(6):S17-20. PubMed ID: 8169377 [Abstract] [Full Text] [Related]
48. Clevidipine: a review of its use in the management of acute hypertension. Deeks ED, Keating GM, Keam SJ. Am J Cardiovasc Drugs; 2009 Dec; 9(2):117-34. PubMed ID: 19331440 [Abstract] [Full Text] [Related]
49. Clinical pharmacology of lacidipine. Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. J Cardiovasc Pharmacol; 1991 Dec; 17 Suppl 4():S9-13. PubMed ID: 1726014 [Abstract] [Full Text] [Related]
53. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, Eckes L, Micheli D, ELSA Investigators. J Hypertens; 2004 Jun 15; 22(6):1201-12. PubMed ID: 15167456 [Abstract] [Full Text] [Related]
54. French large-scale study evaluating the tolerability and efficacy of lacidipine. Tcherdakoff P. J Cardiovasc Pharmacol; 1995 Jun 15; 25 Suppl 3():S27-32. PubMed ID: 8852542 [Abstract] [Full Text] [Related]
57. Impact of calcium antagonists on the cardiovascular system: experience with lacidipine. Kuschnir E. Drugs; 1999 Jun 15; 57 Suppl 1():11-7. PubMed ID: 10529078 [Abstract] [Full Text] [Related]
58. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker]. Sada T, Saito H. Nihon Yakurigaku Zasshi; 2003 Dec 15; 122(6):539-47. PubMed ID: 14639008 [Abstract] [Full Text] [Related]
59. Lacidipine: prevention of vascular damage induced by hypertension. Gaviraghi G, Micheli D, Terron A, Cristofori P. J Cardiovasc Pharmacol; 1991 Dec 15; 18 Suppl 11():S7-12. PubMed ID: 1725448 [Abstract] [Full Text] [Related]